(DMAC) –
-
DiaMedica Therapeutics (DMAC) Files $100M Mixed Shelf
-
Form S-3 DiaMedica Therapeutics
-
DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $8 at Craig-Hallum
-
DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $6 at Oppenheimer
-
Form 10-K DiaMedica Therapeutics For: Dec 31
-
Form 8-K DiaMedica Therapeutics For: Mar 19
-
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
-
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
-
Form 4 DiaMedica Therapeutics For: Jan 22 Filed by: Lorianne Masuoka K.
-
Form 3 DiaMedica Therapeutics For: Jan 22 Filed by: Lorianne Masuoka K.
-
DiaMedica Therapeutics Inc. (DMAC) Appoints Lorianne Masuoka as Chief Medical Officer
-
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
-
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Semba Charles Pauling
-
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Kuntz Richard
-
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Pilnik Richard D.
-
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Parsons James T.
-
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Giuffre Randall Michael
-
Form 4 DiaMedica Therapeutics For: Nov 16 Filed by: Wambeke David J.
-
Form 10-Q DiaMedica Therapeutics For: Sep 30
-
Form 8-K DiaMedica Therapeutics For: Nov 13
-
DiaMedica Therapeutics Inc. (DMAC) Tops Q3 EPS by 1c
-
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
-
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
-
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
-
DiaMedica Therapeutics (DMAC) Appoints Ambarish Shah as CTO
-
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
-
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
-
Form 8-K DiaMedica Therapeutics For: Sep 03
-
Form 10-Q DiaMedica Therapeutics For: Jun 30
-
Form 8-K DiaMedica Therapeutics For: Aug 14
-
DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 2c
-
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
-
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
-
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
-
Form 424B3 DiaMedica Therapeutics
-
Form EFFECT DiaMedica Therapeutics
-
DiaMedica Therapeutics Inc. (DMAC) Announces 11.01M Share Offering by Selling Stockholders
-
Form S-3 DiaMedica Therapeutics
-
Form D DiaMedica Therapeutics
-
Form SC 13G/A DiaMedica Therapeutics Filed by: TRILL AB
-
Form SC 13G/A DiaMedica Therapeutics Filed by: TomEnterprise AB
-
Form 3 DiaMedica Therapeutics For: Jun 23 Filed by: TRILL AB
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: TomEqt Private AB
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: Giuffre Randall Michael
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: Pauls Dietrich John
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: Semba Charles Pauling
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: Kellen Scott
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: Wambeke David J.
-
Form 4 DiaMedica Therapeutics For: Jun 23 Filed by: Pilnik Richard D.
-
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
Back to DMAC Stock Lookup